Hemato Oncology Testing Market

Hemato Oncology Testing is a technology to predict the probability of disease by collecting genes (DNA) in human blood and analyzing and measuring the complete sequence of genes. Genetic testing can identify individuals' genes for disease, thereby preventing or treating tumours earlier.

Hematologic tumor detection is a technique to detect tumor genes on the basis of gene detection. Blood tumor detection services cover a wide range of solid tumors such as lung cancer, breast cancer, stomach cancer, esophageal cancer, colorectal cancer and liver cancer. Common tumors are detected. According to different tumor stages, blood tumor detection can be divided into four categories: tumor susceptibility gene screening, tumor early diagnosis, tumor individualized drug diagnosis, and tumor recovery monitoring. Tumor susceptibility gene screening can help people at high risk of genetic mutations to actively prevent tumors. Early diagnosis of cancer can help patients to find the disease as early as possible, thus greatly improving the survival rate of cancer patients. Individualized drug diagnosis for cancer patients to provide a more accurate cancer treatment program. Tumor recovery was monitored to assess the risk of recurrence.

In this paper, the current status and future development trend of hematoncology testing in China market are studied, focusing on the analysis of the companies that play an important role in the Chinese market, and focusing on the revenue, market share, market positioning, development plans, products and services of these companies in the Chinese market.

Hemato Oncology Testing Market contains market size and forecasts of Hemato Oncology Testing in Global, including the following market information:

Global Hemato Oncology Testing Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Hemato Oncology Testing market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

ctDNA Testing Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hemato Oncology Testing include Roche, Berry Genomics, Burning Rock Dx, BGI, Genetron, Haplox, Amoy Dx, Genosaber and YZY Biopharma and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Hemato Oncology Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hemato Oncology Testing Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Hemato Oncology Testing Market Segment Percentages, by Type, 2021 (%)

ctDNA Testing

CTC Testing

Other Testing

Global Hemato Oncology Testing Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Hemato Oncology Testing Market Segment Percentages, by Application, 2021 (%)

Hospital

Third Party Agency

Others

Global Hemato Oncology Testing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Hemato Oncology Testing Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hemato Oncology Testing revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Hemato Oncology Testing revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Roche

Berry Genomics

Burning Rock Dx

BGI

Genetron

Haplox

Amoy Dx

Genosaber

YZY Biopharma

Wondfo